{"id":"https://openalex.org/W4362609987","doi":"https://doi.org/10.1158/1535-7163.22505797","title":"Supplementary Figures 1-8 from Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions","display_name":"Supplementary Figures 1-8 from Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362609987","doi":"https://doi.org/10.1158/1535-7163.22505797"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.22505797","doi":"https://doi.org/10.1158/1535-7163.22505797","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.22505797","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1535-7163.22505797","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018934270","display_name":"Nicolas Floc\u2019h","orcid":"https://orcid.org/0009-0006-8557-2199","observed_orcids":["https://orcid.org/0009-0006-8557-2199"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nicolas Floc'h","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074879945","display_name":"Matthew J. Martin","orcid":"https://orcid.org/0000-0002-8948-961X","observed_orcids":["https://orcid.org/0000-0002-8948-961X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthew J. Martin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082506495","display_name":"Jonathan Wesley Riess","orcid":"https://orcid.org/0000-0001-7370-7304","observed_orcids":["https://orcid.org/0000-0001-7370-7304"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jonathan W. Riess","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081140523","display_name":"Jonathan P. Orme","orcid":"https://orcid.org/0009-0007-6483-9939","observed_orcids":["https://orcid.org/0009-0007-6483-9939"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jonathan P. Orme","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011515348","display_name":"Anna Dominika Staniszewska","orcid":"https://orcid.org/0000-0003-1328-1959","observed_orcids":["https://orcid.org/0000-0003-1328-1959"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anna D. Staniszewska","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015331828","display_name":"Ludovic M\u00e9nard","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ludovic M\u00e9nard","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027032896","display_name":"Maria Emanuela Cuomo","orcid":"https://orcid.org/0000-0001-6429-2290","observed_orcids":["https://orcid.org/0000-0001-6429-2290"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maria Emanuela Cuomo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101929745","display_name":"Daniel J. O\u2019Neill","orcid":"https://orcid.org/0009-0006-3424-7214","observed_orcids":["https://orcid.org/0009-0006-3424-7214"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel J. O'Neill","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084047203","display_name":"Richard A. Ward","orcid":"https://orcid.org/0000-0002-2310-9477","observed_orcids":["https://orcid.org/0000-0002-2310-9477"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Richard A. Ward","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019998609","display_name":"M. Raymond V. Finlay","orcid":"https://orcid.org/0000-0003-1402-193X","observed_orcids":["https://orcid.org/0000-0003-1402-193X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Raymond V. Finlay","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047398290","display_name":"Darren McKerrecher","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Darren McKerrecher","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079343876","display_name":"Mingshan Cheng","orcid":"https://orcid.org/0000-0002-4261-8007","observed_orcids":["https://orcid.org/0000-0002-4261-8007"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mingshan Cheng","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009392108","display_name":"Daniel P. Vang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel P. Vang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018205931","display_name":"Rebekah A. Burich","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rebekah A. Burich","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033226354","display_name":"James Keck","orcid":"https://orcid.org/0000-0002-6835-5671","observed_orcids":["https://orcid.org/0000-0002-6835-5671"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"James G. Keck","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036091074","display_name":"David R. Gandara","orcid":"https://orcid.org/0000-0003-1784-048X","observed_orcids":["https://orcid.org/0000-0003-1784-048X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David R. Gandara","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010265482","display_name":"Philip C. Mack","orcid":"https://orcid.org/0000-0003-4750-3812","observed_orcids":["https://orcid.org/0000-0003-4750-3812"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Philip C. Mack","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5026352956","display_name":"Darren A.E. Cross","orcid":"https://orcid.org/0000-0002-5227-2871","observed_orcids":["https://orcid.org/0000-0002-5227-2871"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Darren A.E. Cross","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11287","display_name":"Cancer Genomics and Diagnostics","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/osimertinib","display_name":"osimertinib","score":1.0},{"id":"https://openalex.org/keywords/egfr-exon-20-insertion-mutation","display_name":"EGFR exon 20 insertion","score":0.8500000238418579},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9869999885559082},{"id":"https://openalex.org/keywords/cell-proliferation","display_name":"cell proliferation","score":0.6079999804496765},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.8360000252723694},{"id":"https://openalex.org/keywords/patient-derived-xenografts","display_name":"patient-derived xenografts","score":0.8640000224113464},{"id":"https://openalex.org/keywords/afatinib","display_name":"afatinib","score":0.9649999737739563},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/akt-signaling","display_name":"Akt signaling","score":0.8149999976158142},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.6660000085830688},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.6549999713897705}],"concepts":[{"id":"https://openalex.org/C2777626846","wikidata":"https://www.wikidata.org/wiki/Q21506464","display_name":"Osimertinib","level":5,"score":0.9641185998916626},{"id":"https://openalex.org/C2780586478","wikidata":"https://www.wikidata.org/wiki/Q4688818","display_name":"Afatinib","level":5,"score":0.950401782989502},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.7374017834663391},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.548437774181366},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.5077031850814819},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5068457722663879},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.48510730266571045},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.42937329411506653},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.4181830883026123},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.41126811504364014},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3117772936820984},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.29124006628990173},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.27775222063064575},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.23101279139518738},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2307882010936737},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1622902750968933},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.1307069957256317}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1535-7163.22505797","doi":"https://doi.org/10.1158/1535-7163.22505797","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.22505797","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1535-7163.22505797.v1","doi":"https://doi.org/10.1158/1535-7163.22505797.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.22505797.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22505797","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figures_1-8_from_Antitumor_Activity_of_Osimertinib_an_Irreversible_Mutant-Selective_EGFR_Tyrosine_Kinase_Inhibitor_in_NSCLC_Harboring_EGFR_Exon_20_Insertions/22505797","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.22505797","doi":"https://doi.org/10.1158/1535-7163.22505797","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.22505797","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2801802321","https://openalex.org/W4362541946","https://openalex.org/W2793767564","https://openalex.org/W4362491809","https://openalex.org/W2726078708","https://openalex.org/W2740458923","https://openalex.org/W2895414889","https://openalex.org/W2946040207","https://openalex.org/W3113155675","https://openalex.org/W2979281156"],"abstract_inverted_index":{"Supplementary":[0,10,25,43,58,77,99,134],"figure":[1,11,26,44,59,78,100,135],"1:":[2],"Generation":[3],"of":[4,29,35,70,89,92],"H2073":[5,8,13,36,47],"ASV":[6],"and":[7,15,39,62,72,81,94,105,118,139,157,167],"SVD.":[9],"2:":[12],"parental":[14,48],"Ex20Ins":[16],"are":[17,107],"dependent":[18],"on":[19,31],"EGFR":[20],"for":[21],"survival":[22],"in":[23,41,56,114,125,169],"vitro.":[24,42],"3:":[27],"Effect":[28],"TKI":[30],"the":[32,90,95,111,115,126,170,176],"Sytox":[33],"Proliferation":[34],"wt,":[37],"H2073-SVD":[38],"H2073-ASV,":[40],"4:":[45],"The":[46],"NSCLC":[49],"xenograft":[50],"model":[51,128,174],"is":[52],"sensitive":[53],"to":[54,155,165],"afatinib":[55,104,138,166],"vivo.":[57],"5:":[60],"Osimertinib":[61,80],"AZ5104":[63,82,119],"given":[64],"as":[65,83],"monotherapy":[66,84],"induce":[67,85,120],"robust":[68],"inhibition":[69,88,124,154],"p-EGFR":[71],"relevant":[73],"downstream":[74,96,148],"signalling":[75,97,149],"pathways.":[76,98],"6:":[79],"a":[86],"strong":[87],"level":[91],"pEGFR":[93],"7:":[101],"Osimertinib,":[102,137],"AZ5104,":[103],"erlotinib":[106,140,168],"well":[108],"tolerated":[109],"at":[110,131,161],"dose":[112],"explored":[113],"PDX":[116,173],"models":[117],"significant":[121],"tumor":[122],"growth":[123],"LU0387":[127],"when":[129],"dosed":[130],"50":[132],"mg/kg.":[133],"8:":[136],"robustly":[141],"inhibit":[142],"pEGFR;":[143],"however,":[144],"select":[145],"proteins":[146],"representing":[147],"pathways":[150],"(pAKT)":[151],"have":[152],"enhanced":[153],"osimertinib":[156],"pS6R":[158],"remains":[159],"suppressed":[160],"early":[162],"timepoints":[163],"compared":[164],"UC":[171],"Davis":[172],"harboring":[175],"V769_D770InsASV.":[177]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-06T00:00:00"}